Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies.

In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers.

In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences.

The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.

[5] Genome Protection Inc. subsequently received a $10.5 million (US) investment from Russian oligarch Roman Abramovich.